Objective
Recently, the bone marrow was shown to be a site were T cells are primed against blood borne antigens and tumor associated antigens. The common tumor-associated antigen (TAA) MUC1 has been shown to be expressed on about 90% of malignant plasma cells in multiple myeloma (MM). This study was performed to investigate the content and reactivity of MUC-1 specific memory T cells in BM compared to PB from MM patients with respect to possible use in immunotherapeutic strategies.